sur BioNxt Solutions Inc. (CVE:BNXT)
BioNxt Progresses with Semaglutide Oral Film Program
BioNxt Solutions Inc. has successfully completed proof-of-concept trials for its Semaglutide oral dissolvable film (ODF) at its subsidiary, Vektor Pharma in Germany. Among several evaluated proprietary film platforms, one displayed promising results, leading to the creation of Semaglutide-ODF prototypes with impressive characteristics such as rapid disintegration and good manufacturing feasibility.
These developments underscore the technology's suitability for complex peptide formulations, propelling BioNxt's program into its next developmental stage. The company plans to file a patent and optimize formulation, aiming for preclinical tests by 2026.
Semaglutide, known under brands like Ozempic® and Rybelsus®, is gaining global traction in the GLP-1 market, a trend BioNxt aims to leverage with its non-invasive delivery alternative.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de BioNxt Solutions Inc.